Mainz Biomed N.V.
NASDAQ:MYNZ 10:10:12 AM EDT
| Market Cap (Intraday) | 14.85M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.94 |
| 50-Day MA | $0.99 |
| 200-Day MA | $2.03 |
Mainz Biomed N.V. Stock, NASDAQ:MYNZ
Sirius Gutenberg Park, Robert Koch Strasse 50, Mainz, Rheinland-Pfalz 55129
Germany
Phone: +49.6131.55428.60
Number of Employees:
Description
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.